This specific tumor type is well-suited for targeting by CSF-1/CSF-1R pathway blockade; and treatment with anti-CSF-1R antibodies has shown significant reduction of CSF-1R+ TAMs within tumor tissues (97). This evidence concerns the gene CSF1 and neoplasm.